Lv51
1380 积分 2023-02-02 加入
The evolving landscape of drug targets
20天前
已完结
KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial
25天前
已完结
Understanding and overcoming multidrug resistance in cancer
26天前
已完结
Unphosphorylated tyrosines mediate PD-1 inhibition of T cell signaling condensate formation
1个月前
已完结
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
1个月前
已完结
Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial
1个月前
已完结
PU.1 drives psoriasis pathogenesis by promoting intermediate monocytes-to-M1 macrophage differentiation through Dectin-1 signaling
2个月前
已完结
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
2个月前
已完结
Population Pharmacokinetics of Sotorasib in Healthy Subjects and Advanced Solid Tumor Patients Harboring a KRASG12C Mutation from Phase 1 and Phase 2 Studies
2个月前
已完结
KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial
3个月前
已完结
皖公网安备34019202002308
